Imaging of Prostate Cancer Using Urokinase-Type Plasminogen Activator Receptor PET

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

Imaging of Prostate Cancer Using Urokinase-Type Plasminogen Activator Receptor PET. / Skovgaard, Dorthe; Persson, Morten; Kjaer, Andreas.

I: PET Clinics, Bind 12, Nr. 2, 04.2017, s. 243-255.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Skovgaard, D, Persson, M & Kjaer, A 2017, 'Imaging of Prostate Cancer Using Urokinase-Type Plasminogen Activator Receptor PET', PET Clinics, bind 12, nr. 2, s. 243-255. https://doi.org/10.1016/j.cpet.2016.12.005

APA

Skovgaard, D., Persson, M., & Kjaer, A. (2017). Imaging of Prostate Cancer Using Urokinase-Type Plasminogen Activator Receptor PET. PET Clinics, 12(2), 243-255. https://doi.org/10.1016/j.cpet.2016.12.005

Vancouver

Skovgaard D, Persson M, Kjaer A. Imaging of Prostate Cancer Using Urokinase-Type Plasminogen Activator Receptor PET. PET Clinics. 2017 apr.;12(2):243-255. https://doi.org/10.1016/j.cpet.2016.12.005

Author

Skovgaard, Dorthe ; Persson, Morten ; Kjaer, Andreas. / Imaging of Prostate Cancer Using Urokinase-Type Plasminogen Activator Receptor PET. I: PET Clinics. 2017 ; Bind 12, Nr. 2. s. 243-255.

Bibtex

@article{a5f538e8caa44f519c95a3d2265f47b4,
title = "Imaging of Prostate Cancer Using Urokinase-Type Plasminogen Activator Receptor PET",
abstract = "Urokinase-type plasminogen activator receptor (uPAR) overexpression is an important biomarker for aggressiveness in cancer including prostate cancer (PC) and provides independent clinical information in addition to prostate-specific antigen and Gleason score. This article focuses on uPAR PET as a new diagnostic and prognostic imaging biomarker in PC. Many preclinical uPAR-targeted PET imaging studies using AE105 in cancer models have been undertaken with promising results. A major breakthrough was obtained with the recent human translation of uPAR PET in using 64Cu- and 68Ga-labelled versions of AE105, respectively. Clinical results from patients with PC included in these studies are encouraging and support continuation with large-scale clinical trials.",
keywords = "Molecular imaging, PET, Prostate cancer, Radionuclide imaging, Theranostics, uPAR",
author = "Dorthe Skovgaard and Morten Persson and Andreas Kjaer",
year = "2017",
month = apr,
doi = "10.1016/j.cpet.2016.12.005",
language = "English",
volume = "12",
pages = "243--255",
journal = "P E T Clinics",
issn = "1556-8598",
publisher = "W.B.Saunders Co.",
number = "2",

}

RIS

TY - JOUR

T1 - Imaging of Prostate Cancer Using Urokinase-Type Plasminogen Activator Receptor PET

AU - Skovgaard, Dorthe

AU - Persson, Morten

AU - Kjaer, Andreas

PY - 2017/4

Y1 - 2017/4

N2 - Urokinase-type plasminogen activator receptor (uPAR) overexpression is an important biomarker for aggressiveness in cancer including prostate cancer (PC) and provides independent clinical information in addition to prostate-specific antigen and Gleason score. This article focuses on uPAR PET as a new diagnostic and prognostic imaging biomarker in PC. Many preclinical uPAR-targeted PET imaging studies using AE105 in cancer models have been undertaken with promising results. A major breakthrough was obtained with the recent human translation of uPAR PET in using 64Cu- and 68Ga-labelled versions of AE105, respectively. Clinical results from patients with PC included in these studies are encouraging and support continuation with large-scale clinical trials.

AB - Urokinase-type plasminogen activator receptor (uPAR) overexpression is an important biomarker for aggressiveness in cancer including prostate cancer (PC) and provides independent clinical information in addition to prostate-specific antigen and Gleason score. This article focuses on uPAR PET as a new diagnostic and prognostic imaging biomarker in PC. Many preclinical uPAR-targeted PET imaging studies using AE105 in cancer models have been undertaken with promising results. A major breakthrough was obtained with the recent human translation of uPAR PET in using 64Cu- and 68Ga-labelled versions of AE105, respectively. Clinical results from patients with PC included in these studies are encouraging and support continuation with large-scale clinical trials.

KW - Molecular imaging

KW - PET

KW - Prostate cancer

KW - Radionuclide imaging

KW - Theranostics

KW - uPAR

U2 - 10.1016/j.cpet.2016.12.005

DO - 10.1016/j.cpet.2016.12.005

M3 - Review

C2 - 28267457

AN - SCOPUS:85011088562

VL - 12

SP - 243

EP - 255

JO - P E T Clinics

JF - P E T Clinics

SN - 1556-8598

IS - 2

ER -

ID: 196048622